Isis reports more hypertriglyceridemia data
Isis Pharmaceuticals Inc. (NASDAQ:ISIS) said once-weekly subcutaneous doses of 200 and 300 mg ISIS-APOCIIIRx met the co-primary endpoints of reducing apolipoprotein C-III ( APOCIII; APOC3) and triglyceride levels from baseline to week 13 vs. placebo in a second Phase II trial to treat hypertriglyceridemia. The data were from a cohort of 26 patients with high to severely high triglyceride levels (225-2,000 mg/dL) on stable doses of fibrates. Baseline fasting triglyceride levels were 457 mg/dL for placebo patients, 282 mg/dL for patients receiving low-dose ISIS-APOCIIIRx and 384 mg/dL for patients receiving high-dose ISIS-APOCIIIRx.
Shares of Isis barely moved on the data, as investors are likely waiting for the study's monotherapy data in patients with very high to severely high hypertriglyceridemia (440-2,000 mg/dL). The company plans to report those data at the European Society of Cardiology meeting in August. Isis plans to start a Phase III trial early next year to evaluate ISIS-APOCIIIRx in patients with severely high hypertriglyceridemia (>880 mg/dL). ...